Parkinson s Disease - A Junior Doctor s Survival Guide

Size: px
Start display at page:

Download "Parkinson s Disease - A Junior Doctor s Survival Guide"

Transcription

1 Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna<onal Health Northumbria Healthcare NHS Founda<on Trust

2 Geriatricians ideally suited to care for Parkinson s disease Ø Many patients elderly Ø Multiple co-morbidity Ø Multi-system disease Ø Requires multidisciplinary team

3 North Tyneside Prevalence Ø Population of 110,000. Ø Case finding hospital records, GP records (diagnostic lists and drug treatment), other hospitals (eg Neurology). Ø Age-standardised prevalence = 160/100,000. Comparable with previous studies (Porter et al 2006).

4 Aetiological theory for PD

5 What causes Parkinson s? Ageing Genes Environment Parkinson s disease Possible protective effect: smoking and caffeine

6 When do clinical signs of Parkinson's develop? Striatal dopamine levels Reduced by 80% Cell loss in the substantia nigra Reaches 50%

7 The Braak hypothesis Stage 5 and 6: Changes spread to the cortex Stage 3 and 4: Pathology spreads to the midbrain and basal ganglia Stage 1 and 2: Pathology confined to certain structures in the brain stem, not yet the substantia nigra Image adapted from The Professionals Guide to Parkinson s Disease

8 DIAGNOSIS

9 Differential Diagnoses Ø Drug induced parkinsonism Ø Cerebrovascular parkinsonism Ø Lewy body dementia Ø Alzheimers disease Ø Multi system atrophy Ø Progressive supranuclear palsy Ø Benign essential tremor Ø Other weird and wonderful conditions

10 Brain Bank Criteria Ø Developed by PD society brain bank study Ø Retrospectively Ø Sensitivity 96% Ø Specificity 82% Ø Tool now used in epidemiological studies in PD

11 Diagnosis of Parkinsonism - signs Ø BRADYKINESIA and one of: Ø Muscular rigidity Ø 4-6Hz rest tremor Ø Postural instability

12 Probable most important diagnostic criteria Ø Asymmetrical onset Ø Progressive condition Ø Responsive to levodopa

13 Speech Hypomimia Reduced arm swing Posture Tremor Arising from a chair Bradykinesia Rigidity Motor symptoms of Parkinson s Motor symptoms of Parkinson's Postural instability Micrographia Turning in bed Turning Freezing Gait festination Shuffling gait Falls

14 Investigations Ø Routine blood investigations Ø DAT Scan normal in essential tremor and drug-induced Parkinsonism Ø +/- MRI Scan Ø?Dopamine challenge reasonable dose for reasonable length of time Ø Sniffin sticks objective change in sense of smell at diagnosis in over 70%

15 Partnerships in PD PDS Service Users Carers Age Concern Voluntary Bodies Family Health Visitor Consultant Social Worker Person with PD Friends Physiotherapy PD Nurse OT Dietician Psychiatrist GP District Nurse SALT Psychologist

16 The most important partnership Person with PD Person who knows about PD

17 Drug classes in Parkinson s Levodopa MAO-B inhibitors Monoamine oxidase B inhibitors Anticholinergics DAs Dopamine agonists COMTs Catechol-Omethyltransferase inhibitors

18 L-dopa Benefits Disadvantages Most effective symptomatic therapy Good response for morbidity and probably mortality Benefits may be enhanced by: Ø dopamine agonists Ø CR preparations Ø COMT inhibitors Short and long term side effects Complications with longterm use include motor fluctuations and dyskinesias Do not stop disease progression Free radical formation?

19 Specifics of L dopa prescribing Ø Sinemet 110, 125, 275 Halfs etc etc Ø Start low go slow Ø What dose do you go to? Ø CR preparations Ø Dispersible madopar

20 Typical pattern of wearingoff during the day

21 Dopamine agonists Benefits Disadvantages Proven antiparkinsonian activity, although less than levodopa Motor fluctuations and dyskinesias are encountered less if monotherapy Do not produce free radicals Initiation of treatment requires careful dose titration Limited evidence for add on therapy Non-ergolines (ropinirole/ pramipexole) can cause confusion (particularly in the elderly), nausea, dizziness, fainting and daytime sleepiness Ergot-derived agonists (cabergoline, bromocriptine and pergolide) can cause additional, lung and peritoneal fibrosis now not used

22 Impulse Control Disorder A person s inability to resist a temptation or impulse More likely to happen in those with a previous history of novelty seeking or risk taking behaviours Compulsive behaviours have been reported as a side effect with levodopa and dopamine agonists Behaviours can include: l Pathological gambling l Hypersexuality l Compulsive eating l Compulsive shopping l Punding

23 Ø Thalamotomy l Surgery drug-resistant unilateral tremor Ø Pallidotomy l drug-induced dyskinesias Ø Sub-thalamotomy - experimental Ø Stimulation - bilateral l l l thalamic (tremor) bilateral subthalamic nucleus (parkinsonism, tremor, dystonia) pallidal (dyskinesias)

24 Non-motor symptoms Neuropsychiatric Autonomic Sleep disturbance Sensory symptoms Dementia Depression Apathy Anxiety Loss of libido REM sleep disorder RLS Vivid dreams Daytime somnolence Dystonia Constipation Urinary incontinence Erectile dysfunction Excessive sweating Postural hypotension Excessive salivation Pain Paraesthesia

25 Sleep Disorders Ø Two thirds of patients Ø Insomnia l l Initial Sleep maintenance (sleep fragmentation) Parasomnias l l REM sleep behaviour disorder Vivid dreams Ø Excessive daytime sleepiness and sleep attacks Ø Obstructive sleep apnoea and stridor (NB MSA)

26 NEUROPSYCHIATRIC COMPLICATIONS

27 Ø Depression Ø Anxiety and agitation Ø Sleep disturbances Ø Vivid dreams Ø Hallucinations Ø Delirium Ø Dementia

28 Confused patient Ø Delirium screen Ø Decrease PD medication in following order l Anticholinergic, Amantadine, MAOIB, DA, COMT-I, LD Ø Consider atypical neuroleptic, eg Quetiapine (Clozapine) start at low dose of 12.5mgs Ø Cholinesterase inhibitors, eg Donepezil, Rivastigmine (NB patch) may improve cognition and hallucinations

29 Swallowing problems Ø Look for reversible cause Ø Get PD medication into patient l NG tube l Rotigotine patch l Apomorphine subcutaneously (NB Domperidone) Ø Don t consider for end of life care unless adequate dopaminergic replacement, or on advice from PD specialist team

30 General tips for inpatients Ø Make sure they get medication on time Ø Know how to contact PD specialist team, eg PD nurse specialist will often know patients well Ø Ask about hallucinations Ø Any illness will often make PD symptoms worse, and it takes PD patients longer to recover

31 Useful Contacts for PD Ø Parkinson s UK Ø BGS movement disorders section Ø richard.walker@nhct.nhs.uk

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making

More information

Dementia & Movement Disorders

Dementia & Movement Disorders Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia

More information

PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB

PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety

More information

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of

More information

Management of Parkinson s Disease in Primary Care

Management of Parkinson s Disease in Primary Care Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo

More information

Parkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician

Parkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician Parkinson s Disease and Dementia Dr N Samaniego Consultant Physician and Geriatrician Case 68 year old female. Off legs for a few months, O/E no neurological deficit. -Slowing down -Needs help with dressing,

More information

GLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s.

GLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s. Antagonist This glossary explains the terms and words often used in association with Parkinson s. Medications which have a negative effect on particular cells in the body. In Parkinson s dopamine antagonists

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible

More information

Lewy body dementia Referral for a Diagnosis

Lewy body dementia Referral for a Diagnosis THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia

More information

Parkinson's s disease - a

Parkinson's s disease - a Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability

More information

Understanding Parkinson s Disease

Understanding Parkinson s Disease Understanding Parkinson s Disease Irene Oh, MD Neurologist, Movement Disorders Specialist The Neurology Center of Southern California, Encinitas & Escondido Introduction PD was first described in 1817

More information

The majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma.

The majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma. THE TREATMENT OF PARKINSON S DISEASE SUMMARY Levodopa (L-dopa) administered in conjunction with a dopa decarboxylase inhibitor (DDCI) remains the mainstay of therapy for Parkinson s disease. New drugs

More information

An Introduction to Lewy Body Dementia

An Introduction to Lewy Body Dementia An Introduction to Lewy Body Dementia A special publication for people newly diagnosed with Lewy body dementia and those still seeking answers. You don t have to face LBD alone. Increasing Knowledge Sharing

More information

Emergency Room Treatment of Psychosis

Emergency Room Treatment of Psychosis OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

More information

How To Treat Aphasic Depression

How To Treat Aphasic Depression Antipsychotic Use in Patients with Parkinson s Disease 단국의대 정신과 이석범 Difficulties in Parkinson's disease Motor symptoms Neuropsychiatric syndromes Severe Disability Cognitive impairment 2 Neuropsychiatric

More information

Acute management of Parkinson s

Acute management of Parkinson s Acute management of Parkinson s Fife Parkinson s Service 2013 1 Contents 1. Introduction 2. On admission to hospital 3. If Patient has compromised swallow or is nil by mouth 4. Conversion charts if patient

More information

Mr James Garrard University of Leicester May 2014

Mr James Garrard University of Leicester May 2014 Parkinson s disease exemplifies the art and science of geriatric medicine. Introduction First described by Dr. James Parkinson in the classic essay The Shaking Palsy in 1817 (1), Parkinson s disease is

More information

Personal Health Record

Personal Health Record Personal Health Record Contents Section 1: Personal details (pages 4 6) Within this section you can note all information about you, next of kin, important health information and general medical history.

More information

Diagnosing Parkinson s disease (PD) in

Diagnosing Parkinson s disease (PD) in MedicineToday 2015; 16(1): 12-18 PEER REVIEWED FEATURE 2 CPD POINTS The clinical challenge of early Parkinson s disease SIMON J.G. LEWIS MB BCh, BSc, MRCP, FRACP, MD Early Parkinson s disease may be challenging

More information

Parkinson s Disease and Tremors

Parkinson s Disease and Tremors Parkinson s Disease and Tremors Current Strategies Leah Karliner, MD, MAS Division of General Internal Medicine Disclosures I have no conflicts of interest Parkinsonism neurological syndrome: Bradykinesia:

More information

Motor Fluctuations in Parkinson s

Motor Fluctuations in Parkinson s Motor Fluctuations in Parkinson s What are motor fluctuations? Motor fluctuations are associated with longterm use of levodopa (trade names Sinemet or Madopar, Co-careldopa or Co-beneldopa), and usually

More information

Chapter 28. Drug Treatment of Parkinson s Disease

Chapter 28. Drug Treatment of Parkinson s Disease Chapter 28 Drug Treatment of Parkinson s Disease 1. Introduction Parkinsonism Tremors hands and head develop involuntary movements when at rest; pin rolling sign (finger and thumb) Muscle rigidity arthritis

More information

Management of Parkinson s disease and co-existent health problems is a long journey, requiring a multidisciplinary team approach.

Management of Parkinson s disease and co-existent health problems is a long journey, requiring a multidisciplinary team approach. Diagnosis and management of Parkinson s Disease Key points 1. 2. 3. 4. 5. 6. The diagnosis of Parkinson s disease is still based on careful history taking and clinical examination, despite ongoing advances

More information

A GUIDE FOR THE NEW PATIENT. supported by the Neurological Foundation

A GUIDE FOR THE NEW PATIENT. supported by the Neurological Foundation PARKINSON S A GUIDE FOR THE NEW PATIENT supported by the Neurological Foundation INTRODUCTION 1 Contents 1. Introduction 2. Parkinson s 3. The main symptoms of Parkinson s 6. What causes Parkinson s? 7.

More information

Parkinson s disease. 14 June 2012

Parkinson s disease. 14 June 2012 Parkinson s disease 14 June 2012 Cardinal sign of parkinsonism As least 2/4 for diagnosis Resting tremor Bradykinesia Rigidity Postural instability Classification Idiopathic Parkinson disease Secondary

More information

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

More information

PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.

PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement. PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common

More information

Nursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014

Nursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014 Nursing Care of Patients with Movement Disorders Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014 Types of Movement Disorders Parkinson s disease Huntington s disease Dystonia Tremors

More information

Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm)

Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm) Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm) Accessing information on Multiple System Atrophy (MSA) can be hard work. The Sarah Matheson Trust (SMT) produces a guide to MSA that

More information

SLEEP AND PARKINSON S DISEASE

SLEEP AND PARKINSON S DISEASE A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are

More information

Clinical Psychopharmacology

Clinical Psychopharmacology Clinical Psychopharmacology Antiparkinsonian drugs Department of Pharmacy, GGZ WNB Chair on Pharmacotherapy in Psychiatric Patients/Anton Loonen May 2015 2 Basal ganglia diseases Parkinson s disease and

More information

Parkinson s Disease Symptoms Guide

Parkinson s Disease Symptoms Guide Parkinson s Disease Symptoms Guide Some symptoms of Parkinson s disease (PD) are hard for even specialists to detect. Others are obvious even to an untrained eye. Parkinson s symptoms are different for

More information

Disordered sleep at night has long been

Disordered sleep at night has long been Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects

More information

Parkinson s Disease: Factsheet

Parkinson s Disease: Factsheet Parkinson s Disease: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Parkinson s disease (PD) is a progressive neuro-degenerative condition that affects a person s

More information

Parkinson s Disease: General Information

Parkinson s Disease: General Information Parkinson s Disease: General Information Does PD come in stages? If so, how many stages? Hubert Fernandez, MD: Staging provides an artificial classification of a patient's illness severity but, in reality,

More information

Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature

Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature Evidence Report/Technology Assessment Number 57 Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature Prepared for: Agency for Healthcare Research and Quality U.S. Department

More information

Part 1 of a 6-Part Series

Part 1 of a 6-Part Series Release Date: April 1, 2003. Termination Date: April 1, 2004. Estimated time to complete this 6-part newsletter series: 3.0 hours. For additional updates, go to www.projectsinknowledge.com Awake and Involved:

More information

SIGN. Diagnosis and pharmacological management of Parkinson s disease. January 2010. A national clinical guideline

SIGN. Diagnosis and pharmacological management of Parkinson s disease. January 2010. A national clinical guideline SIGN Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland Help us to improve SIGN guidelines - click here to complete our survey 113 Diagnosis and pharmacological management

More information

drug treatments for parkinson s

drug treatments for parkinson s drug treatments for parkinson s While there is no cure yet for Parkinson s, there are many different drugs that can help manage the symptoms. This booklet is for people with Parkinson s and their families.

More information

EBM Parkinson s Diseases

EBM Parkinson s Diseases Parkinson s Diseases Version 1 Final Page 1 Document control Version history Version Date Comments 1e (draft) 30 March 2007 Comments from customer incorporated 1d (draft) 22 January 2007 Formatting 1c

More information

Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training

Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training Marian A. Ormont, MD epharmasolutions, A WIRB-Copernicus Group Company April is Parkinson s disease

More information

Anti-Parkinsonism Drugs

Anti-Parkinsonism Drugs Anti-Parkinsonism Drugs Pharma Team 429 Fahad Alrumaih Ibrahim Alshiddi Sultan Alsalem Ismail Raslan Suhail Asiri Parkinsonism - Could be: primary [idiopathic] or secondary [viral infection or drug induced

More information

PARKINSONISM. akinetic-rigid syndrome

PARKINSONISM. akinetic-rigid syndrome PARKINSONISM PARKINSONISM akinetic-rigid syndrome PARKINSONISM Symptoms of Parkinson s disease: akinesia, bradykinesia, rigidity, postural instability, gait impairment, tremor A common, age-related syndrome

More information

Sleep and Night-time Problems in Parkinson s What are the causes of sleep disruption in Parkinson s? Parkinson s Disease Society

Sleep and Night-time Problems in Parkinson s What are the causes of sleep disruption in Parkinson s? Parkinson s Disease Society Sleep and Night-time Problems in Parkinson s Most people with Parkinson s experience problems with sleeping at night. A recent survey suggested that up to 90 percent of people with the condition experience

More information

NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute

NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute NEW PATIENT CLINICAL INFORMATION FORM Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute Date: Name: Referring Doctor: How did you hear about us? NWPF Your Physician:

More information

Current evidence suggests that Parkinson s tends to develop

Current evidence suggests that Parkinson s tends to develop About Parkinson's Diagnosing Parkinson s Current evidence suggests that Parkinson s tends to develop gradually and it may be many months, even years, before the symptoms become obvious enough for you to

More information

Unmet Needs for Parkinson s Disease Therapeutics

Unmet Needs for Parkinson s Disease Therapeutics Unmet Needs for Parkinson s Disease Therapeutics Coalition Against Major Diseases & FDA Workshop October 20, 2014 Caroline M Tanner MD, PhD Director, Parkinson's Disease Research Education and Clinical

More information

Parkinson s Disease (PD)

Parkinson s Disease (PD) Parkinson s Disease (PD) Parkinson s disease (PD) is a movement disorder that worsens over time. About 1 in 100 people older than 60 has Parkinson s. The exact cause of PD is still not known, but research

More information

Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease

Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect

More information

Ronald Postuma, Christos Galatas. A Guide to the Non-Motor Symptoms. Parkinson s Disease. A patient-friendly booklet for:

Ronald Postuma, Christos Galatas. A Guide to the Non-Motor Symptoms. Parkinson s Disease. A patient-friendly booklet for: Ronald Postuma, Christos Galatas A Guide to the Non-Motor Symptoms of Parkinson s Disease A patient-friendly booklet for: This booklet is to help you understand Parkinson s Disease and prepare for the

More information

Dementia with Lewy bodies

Dementia with Lewy bodies IS 18 April 2011 Information sheet Dementia with Lewy bodies Introduction... 1 Key points... 1 What is dementia with Lewy bodies?... 1 How many people are affected by DLB?.. 2 What is the cause?... 2 Symptoms...

More information

Levels of evidence and grades of recommendation

Levels of evidence and grades of recommendation MOH Clinical Practice Guidelines 6/2007 Levels of evidence and grades of recommendation Levels of Evidence Level Type of Evidence 1 ++ High quality meta analyses, systematic reviews of RCTs, or RCTs with

More information

NEUROIMAGING in Parkinsonian Syndromes

NEUROIMAGING in Parkinsonian Syndromes NEUROIMAGING in Parkinsonian Syndromes (Focus on Structural Techniques: CT and MRI) Dr. Roberto Cilia Parkinson Institute, ICP, Milan, Italy OUTLINE Primary Parkinsonism Idiopathic Parkinson s Disease

More information

PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O.

PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O. PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O. Parkinson's disease is a common neurologic disorder. It affects people of all ages and ethnic backgrounds and

More information

Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD

Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the

More information

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical

More information

COMPASS Therapeutic Notes on Management of Parkinson s Disease

COMPASS Therapeutic Notes on Management of Parkinson s Disease COMPASS Therapeutic Notes on Management of Parkinson s Disease In this issue Page Introduction 1 Drug Treatment in 3 early PD Motor 9 complications Depression in PD 11 Dementia in PD 13 Psychosis in PD

More information

Neuropharmacology I Parkinson s Disease and Movement Disorders

Neuropharmacology I Parkinson s Disease and Movement Disorders Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Dr. David Standaert Standaert 1 Neuropharmacology I Parkinson s Disease and Movement Disorders What

More information

III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases

III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2.1. Multiple System Atrophy (MSA) MSA is a sporadic, adult onset degenerative neurological

More information

Information for Patients, Families, and Professionals

Information for Patients, Families, and Professionals Lewy Body Dementia Information for Patients, Families, and Professionals LEARN ABOUT: Dementia with Lewy bodies Parkinson s disease dementia National Institute on Aging National Institute of Neurological

More information

Parkinson s Disease. s i x t h E D i t i O N

Parkinson s Disease. s i x t h E D i t i O N Parkinson s Disease & s i x t h E D i t i O N Dear Friends: People affected by Parkinson s disease those living with Parkinson s, their family members, their friends and the health care professionals

More information

SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.

SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to

More information

Parkinson's disease. Definition. Symptoms

Parkinson's disease. Definition. Symptoms Parkinson's disease Definition Parkinson's disease is a progressive disorder of the nervous system that affects your movement. It develops gradually, sometimes starting with a barely noticeable tremor

More information

drug treatments for parkinson s

drug treatments for parkinson s drug treatments for parkinson s 1 While there is no cure yet for Parkinson s, there are many different drugs that can help manage the symptoms. This booklet is for people with Parkinson s and their families.

More information

Clinical guideline Published: 28 June 2006 nice.org.uk/guidance/cg35

Clinical guideline Published: 28 June 2006 nice.org.uk/guidance/cg35 Parkinson's disease in over 20s: diagnosis and management Clinical guideline Published: 28 June 2006 nice.org.uk/guidance/cg35 NICE 2006. All rights reserved. Contents Introduction... 4 Patient-centred

More information

SUMMARY OF RECOMMENDATIONS

SUMMARY OF RECOMMENDATIONS SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*

More information

How To Treat An Elderly Patient

How To Treat An Elderly Patient 1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity

More information

Prevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders

Prevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders Research papers Prevalence of and its aetiological subtypes within patients with movement disorders D G S V D Gajasinghe* AL 2002 batch of students, Faculty of Medicine, University of Colombo Abstract

More information

Chad Christine, MD UCSF

Chad Christine, MD UCSF Parkinsonism: Clinical Features and Treatments Parkinson's disease is a condition whose main features are slowed movement, tremor, and gait or balance problems. More than1 million people in the United

More information

Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022

Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2834728/ Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022 Description: Sinemet (Parkinson s Disease) - Forecast

More information

Depression is a common biological brain disorder and occurs in 7-12% of all individuals over

Depression is a common biological brain disorder and occurs in 7-12% of all individuals over Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),

More information

Lecture Objectives/ Goals

Lecture Objectives/ Goals Lewy Body Dementia: Challenges and Treatment Karen Mullins, D.O. Knoxville Neurology Clinic Lecture Objectives/ Goals Be familiar with signs and symptoms of the pt with LBD Review pathophysiology of LBD

More information

9/20/2010. The eye doesn t see what the mind doesn t know. Sir William Osler

9/20/2010. The eye doesn t see what the mind doesn t know. Sir William Osler The eye doesn t see what the mind doesn t know. Sir William Osler Lewy Body Dementia Atypical Dementia The Lewy Body Spectrum Patricia J. Gifford, MD Silverado Hospice 2009 Progressive loss of intellectual

More information

Memantine (Ebixa) Drug treatment for Alzheimer s disease

Memantine (Ebixa) Drug treatment for Alzheimer s disease IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How

More information

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013 Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human

More information

Recognition and Treatment of Depression in Parkinson s Disease

Recognition and Treatment of Depression in Parkinson s Disease Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,

More information

Journal Club. Parkinsonismo iatrogeno

Journal Club. Parkinsonismo iatrogeno PROGETTO UNIVA 2013 Journal Club Parkinsonismo iatrogeno Pietro Gareri, MD, PhD Geriatra ASP Catanzaro Lamezia Terme 3 Luglio 2013 Drug-induced parkinsonism (DIP) was recognized in the early 1950s as a

More information

Parkinson s Disease. Challenges, Progress and Hope

Parkinson s Disease. Challenges, Progress and Hope Parkinson s Disease Challenges, Progress and Hope Parkinson s Disease: Challenges, Progress and Hope Course #226 5 Contact Hours Author: Ellen Steinbart, RN, MA Course Material valid through 09/2016 Copyright

More information

PARTNERS IN PARKINSON S. Parkinson s Disease Guide

PARTNERS IN PARKINSON S. Parkinson s Disease Guide PARTNERS IN PARKINSON S Parkinson s Disease Guide Each individual travels his or her own journey with Parkinson s disease, often encountering new challenges as symptoms progress and care needs change.

More information

ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD

ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,

More information

UNIFIED PARKINSON'S DISEASE RATING SCALE

UNIFIED PARKINSON'S DISEASE RATING SCALE UNIFIED PARKINSON'S DISEASE RATING SCALE I. MENTATION, BEHAVIOR AND MOOD 1. Intellectual Impairment ne. 1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties.

More information

HOW TO HELP HURTING PEOPLE (YOURSELF AND OTHERS)

HOW TO HELP HURTING PEOPLE (YOURSELF AND OTHERS) HOW TO HELP HURTING PEOPLE (YOURSELF AND OTHERS) An Introduction to Biblical Counseling DISCLAIMER DISCLAIMER I m not here to upset you. DISCLAIMER I m not here to upset you. I m not here to give medical

More information

2014 recommendations for the treatment. of Parkinson s disease. Working Group of the Therapy Commission of the Swiss Neurological Society 1

2014 recommendations for the treatment. of Parkinson s disease. Working Group of the Therapy Commission of the Swiss Neurological Society 1 2014 recommendations for the treatment Working Group of the Therapy Commission of the Swiss Neurological Society 1 Funding / potential competing interests: No financial support and no other potential conflict

More information

Pharmacological Management of Parkinson s Disease Robert Iansek

Pharmacological Management of Parkinson s Disease Robert Iansek GERIATRIC THERAPEUTICS Editors: Associate Professor Michael Woodward, Director, Aged and Residential Care Services, Dr Margaret Bird, Consultant Geriatrician, Mr Rohan Elliott, Clinical Pharmacist, Austin

More information

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects

More information

Parkinson s disease (PD) is a progressive neurodegenerative

Parkinson s disease (PD) is a progressive neurodegenerative n reports n Advanced Strategies for Treatment of Parkinson s Disease: The Role of Early Treatment Michael W. Jann, PharmD Parkinson s disease (PD) is a progressive neurodegenerative disease associated

More information

cme: The Current Treatment of Parkinson's Disease

cme: The Current Treatment of Parkinson's Disease cme: The Current Treatment of Parkinson's Disease Lars Wojtecki, Martin Südmeyer, Alfons Schnitzler SUMMARY Introduction: Parkinson s disease is a neurodegenerative disease characterized by akinesia, rigidity,

More information

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSONS DISEASE

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSONS DISEASE CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE Summary This guideline covers the management of patients with Parkinson s disease including management of medication, confusion,

More information

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011 Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both

More information

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this

More information

Public Assessment Report. Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS

Public Assessment Report. Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS Public Assessment Report Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS Summary 2 Introduction 4 Data considered 5 Published literature 9 Discussion 14 Conclusions and

More information

Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders

Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders Karen Frei, Erik Ch. Wolters Abstract: The twentieth World Congress on Parkinson s Disease and Related Disorders was held

More information

What You and Your Family Should Know

What You and Your Family Should Know Parkinson s Disease: What You and Your Family Should Know Edited by Gale Kittle, RN, MPH Table of Contents Chapter 1: Parkinson s Disease: A Basic Understanding... 3 Chapter 2: Chapter 3: Chapter 4: Chapter

More information

Disorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis

Disorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis Disorders Considered A Brief Synopsis of Select Neurological Disorders Four neurological disorders are examined to illustrate pathological conditions that can develop related to course material Myasthenia

More information

Parkinson s Disease Medications

Parkinson s Disease Medications Parkinson s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest author Melanie Brandabur, MD Table of Contents Chapter 1 Introduction to Parkinson s

More information

DRUG-INDUCED COMPULSIVE BEHAVIOUR IN PARKINSON S: CLINICAL AND LEGAL IMPLICATIONS ADRIAN CARTER AND WAYNE HALL

DRUG-INDUCED COMPULSIVE BEHAVIOUR IN PARKINSON S: CLINICAL AND LEGAL IMPLICATIONS ADRIAN CARTER AND WAYNE HALL DRUG-INDUCED COMPULSIVE BEHAVIOUR IN PARKINSON S: CLINICAL AND LEGAL IMPLICATIONS ADRIAN CARTER AND WAYNE HALL UQ CENTRE FOR CLINICAL RESEARCH THE UNIVERSITY OF QUEENSLAND COLLABORATION Nadeeka Dissanayaka,

More information

MOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP

MOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP MOTION AND E-MOTION Andrea Cavanna MD PhD FRCP Consultant in Behavioural Neurology, BSMHFT, Birmingham, UK Hon Professor in Neuropsychiatry, Aston University, Birmingham, UK Hon Reader in Neuropsychiatry,

More information

Medication Management of Lewy Body and Parkinson's Dementias

Medication Management of Lewy Body and Parkinson's Dementias Medication Management of Lewy Body and Parkinson's Dementias Jill Kauer, PharmD, MSPhr, BCPP September 2014 Disclosure Statement I, Jill Kauer, PharmD, MSPhr, BCPP do not have any financial interests or

More information

Parkinsonism is an umbrella term used to cover a range of conditions.

Parkinsonism is an umbrella term used to cover a range of conditions. Symptoms and lifestyle Parkinsonism Parkinsonism is an umbrella term used to cover a range of conditions. These conditions share the symptom of slow movement, sometimes with tremor, rigidity and problems

More information

CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE

CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE Charbel MACARI Physical Therapist, AUBMC Master in Neurological Rehabilitation OUTLINE Definition, Epidemiology and

More information